Biocon Chairman Kiran Mazumdar-Shaw On Hopes For An Oral Diabetes Drug, And Risks And Rewards Of Innovation: An Interview with PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Biocon Chairman And Managing Director Kiran Mazumdar-Shaw shares her business development strategy and newest pipeline developments with PharmAsia News in an exclusive interview.
You may also be interested in...
Are Biosimilars The Next Big Opportunity In India?
MUMBAI - The Indian biosimilars market is a multi-billion dollar opportunity for Indian and multinational companies to tap into, albeit via different routes, according to a white paper released this month by global consultancy Frost & Sullivan
India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
MUMBAI - Indian biotechnology firm Biocon has reinforced its ambitions to bring to market an orally delivered insulin and said it stays firmly on track as it found several "unique and positive" takeaways from its recently concluded Phase III clinical trials in India
Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma
MUMBAI - India's flagship biotechnology company Biocon suffered a significant setback to its most ambitious research project - an orally delivered insulin - that failed to meet its primary end point of lowering HbA1c levels by 0.7 percent in a clinical study concluded recently in India